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Abstract The ability of a rigid α-Tn mimetic (com-
pound 1) to activate murine invariant natural killer T
(iNKT) and human natural killer (NK) cells, two subsets
of lymphocytes involved in cancer immunesurveillance,
was investigated. For this purpose, the mimetic 1 was
properly conjugated to a stearic acid containing
glycerol-based phospholipid (compound 5) to be pre-
sented, in the context of the conserved non polymorphic
major histocompatibility complex class I-like molecules
(CD1d), to iNKT cells. On the contrary, the mimetic 1
was conjugated to a multivalent peptide-based scaffold
(compound 6) to induce NK cell activation.
Keywords Invariantnatural killerTcells .Naturalkiller cells .
α-Tn antigen . Glycomimetic . Immunotherapy
Introduction
During the last decade, substantial pieces of evidences
showed the importance of the immune system in fight-
ing cancer. The immune system can, indeed, regulate
tumor development/suppression through a sequence of
complex events that starts with the recognition of tumor
cells and goes on with a crosstalk among immune cells.
This process may lead to immune cell infiltration within
the tumor with possible malignant cell killing or con-
duct to a temporary state of dynamic equilibrium be-
tween immunosurveillance and tumor growth. If the im-
mune system fails to eliminate tumors completely, tu-
mors try to protect themselves by creating a permissive
microenvironment and a resistant tumor phenotype able
to escape the immunosurveillance [1, 2]. In this frame-
work, the immunotherapy, an old therapeutic approach
[3] improved in the last few years, appeared to be an
appealing strategy [4] to circumvent the tumor-induced
immune suppression through the breakthrough of the
Bcheckpoint blockades^ [5–7].
A multi-targeting approach to fight tumor cells is, at pres-
ent, of growing interest [8–13]. For example, the delivery of
tumor-targeted antigens [11, 13] through the introduction of
targeting moieties covalently linked to tumor antigens. This
procedure could drive antigen-specific immune responses by
harnessing stimulatory functions of specific subsets of im-
mune cells. Synthetic architectures can be assembled to bind
to specific receptors on immune cells, or spatial arrangement/
multivalent presentations of conjugated antigens can be
designed.
Among other cells of the immune system, invariant natural
killer T (iNKT) and natural killer (NK) cells, consisting of a
subse t o f lymphocy tes , p l ay essen t i a l ro les in
immunesurveillance and represent potential targets for
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immunotherapy. These cells, even if they share some pheno-
typical and functional similarities, exert non-redundant and
specific functions [14].
In particular, human iNKTcells are a small proportion of T
lymphocytes, expressingαβTcell receptor (TCR) and natural
killer (NK) cell lineage markers (e.g., CD161), which exhibit
functional properties of both conventional T and NK cells
[15]. They express an invariant TCR-α chain (Vα24-Jα18),
paired with the semi-invariant TCR-β chain (Vβ11), that rec-
ognize lipid antigens when presented in the context of the
conserved non polymorphic major histocompatibility com-
plex class I-like molecules (CD1d) [16, 17]. Despite their
invariant TCR, iNKT cells are able to recognize a diverse
range of antigens, ranging from foreign microbials to endog-
enous lipids [18], and rapidly and specifically respond against
stimulation. Depending on the structure of lipid antigens and/
or cytokine stimuli iNKT cells can release a diverse range of
cytokines (i.e., IFN-γ, IL-4) and chemokines (i.e., RANTES,
eotaxin) [19], and up-regulate different costimulatory mole-
cules (i.e., CD28, CD40L) [20], as well as cytotoxicity recep-
tors (i.e., NKG2d) and mediators (i.e., perforine and gran-
zyme) [21]. Through these signals iNKT cells can influence
the activation/differentiation of dendritic cells (DCs), B and T
lymphocytes, as well as NK cells, macrophages, and
granulocytes. In the context of tumor immunity, iNKT cells
play a critical role in immunosurveillance, even if the mecha-
nisms underlying iNKT cell activation during tumor growth
remain elusive.
On the other hand, NK cells are lytic lymphocytes, which
mediate rapid effector responses without any priming [22, 23].
NK cells, compared to T or B lymphocytes, do not express
clonally distributed receptors for antigens, [24, 25] but they
have a plethora of germ-line encoded inhibitory/activating
receptors [26]. In particular, the inhibitory receptors recognize
the self-major histocompatibility complex class I (MHC-I)
molecules preventing NK cell activation, while the activating
receptors recognize the pathological cells, having the MHC-I
molecules down-regulated [27] and/or the Bstress-induced^
self proteins up-regulated [28]. NK cells are able to kill dan-
gerous cells in few minutes by two main mechanisms: i) the
interaction of specific cell surface ligands (e.g., FasL) with
death receptors (e.g., Fas/CD95) expressed on transformed/
damaged cells; ii) the release of lytic granules, containing
perforin and granzyme molecules, which can destroy target
cells within hours trough cytotoxic activities similar to that
of CD8+ cytotoxic T lymphocytes [29]. In addition, NK cells,
once activated, release various cytokines/chemokines able to
influence the functions of both adaptive and innate immune
system [30–33]. Recently, the immunological role of these
cells appeared to be more complex, extending beyond the
classical Binnate^ time-frame towards functional features of
adaptive immunity, such as longevity and immunological
memory [34–36].
On the basis of these evidences, the aim of the pres-
ent study was to investigate the activity of the fully
synthetic antigen 1 [37, 38] (Fig. 1) on iNKT and NK
cell activation. Compound 1 is the first example of a
conformationally constrained mimetic of the well-
studied α-Tn-antigen 2 [39], a hapten expressed on dif-
ferent kind of cancer cells.
Recently, some of us successfully demonstrated that the Tn
mimetic 1 (Fig. 1), when properly functionalized on the car-
boxylic group with a suitable architecture, is able to trigger
different immune cells and induce specific and long-lasting
immune responses [40]. In particular: i) biocompatible and
immunogenic iron oxide superparamagnetic nanoparticles 3
(Fig. 1), decorated with high density of the Tn mimetic 1,
induce a specific macrophage activation [41]; ii) the synthetic
peptide-based glyco-cluster 4 (Fig. 1), which provided the
multivalent presentation of the mimetic 1, elicits significant
IgG/IgM mAb production and protection in mice affected by
breast cancer [40]. The overall data confirm that the biological
effect of the Tn-mimetic 1 can be modulated by changing the
nonglycan portion of the conjugate.
Thus, following this concept and looking for an ade-
quate and multi-target immune response, we here inves-
tigated the ability of the rigidified mimetic 1 to induce
iNKT and NK cells activation. To gain this goal, both
the glycoconjugates 5 and 6 were selected (Fig. 2). In
particular, the glycolipid 5, which consists of a stearic
acid containing glycerol-based phospholipid conjugated
to a residue of the Tn-mimetic 1, was chosen because
of its ability to be presented by CD1d [42] to induce
iNKT cell activation (T-cell-antigen presenting assay).
On the contrary, taking into account that the multivalent
presentation of 1 is important to modulate the induced
immune response [40] the hexavalent glycopeptide 6
was also included in the study. Indeed, the glycopeptide
6 consists, of a cyclopeptide scaffold, termed regioselec-
tively addressable functionalized template (RAFT) [43],
where six residues of 1, four on the upper face and two
on the lower face of the RAFT, were conjugated to the
lysine lateral chains. The ability of 6 to activate NK
cells was assessed by measuring the expression of
CD107a (degranulation assay).
Materials and methods
Materials
Reagents were purchased from commercial suppliers and
used without purification. ESI-MS mass spectra were
recorded on a LCQ-Fleet Ion Trap equipped with a
standard Ionspray interface from Thermo Scientific.
NMR spectra were recorded on Varian Gemini 300,
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Mercury Plus 400, Bruker AVANCE 500. [α]D values
were measured using a JASCO DIP-370 instrument.
Protected amino acids and Fmoc-Gly-Sasrin resin were
obtained from Advanced ChemTech Europe (Brussels,
Belgium), Bachem Biochimie SARL (Voisins-Les-
Bretonneux, France) and France Biochem S.A.
(Meudon, France). PyBOP was purchased from France
Biochem. Reaction progress was monitored by reverse-
phase HPLC on Waters equipment using C18 columns.
Analytical and preparative separation was carried out at
1.0 mL/min (EC 125/3 nucleosil 300–5 C18) and at
22 mL/min (VP 250/21 nucleosil 300–7 C18) with UV
monitoring at 214 nm and 250 nm using a linear A–B
gradient (buffer A: 0.09% CF3CO2H in water; buffer B:
0.09% CF3CO2H in 90% acetonitrile). Cyclopeptides
were analyzed by mass spectrometry using electrospray
ionization on an Esquire 3000+ Bruker Daltonics in
positive mode.
Chemistry
Synthesis of 9
To a stirred solution of TBTU (0.033 g, 0.104 mmol) in
dry DMF (0.6 mL) NMM (0.012 mL, 0.104 mmol) was
added. The mixture was left strirring for 15 min at r.t than
a solution of 7 (0.024 g, 0.052 mmol) in DMF (0.4 mL)
was added. The reaction mixture was left stirring for
10 min than a solution of 8 in dry CH2Cl2:CHCl3 (3:1)
was added. The mixture was warmed at 40 °C for 1 h
then cooled to r.t and left stirred for 15 h. After this time
the reaction mixture was diluted with CH2Cl2 (100 mL)
and washed with H2O (1 × 10 mL), a 1 M solution of
Triethylammonium bicarbonate (1 × 15 mL). The organic
phase was dried over Na2SO4 and concentrated to dryness
to give a crude which was purified by flash chromatogra-
phy on silica gel (AcOEt +0.1% NEt3 ➔ DCM: MeOH 5:
1 + 0 . 1% NE t 3 ) . C a t i o n c e x c h ang e o f t h e
triethylammonium salt of 9 with amberlite resin IR-120
Na+ (CHCl3: MeOH 2:1) gave 9 (0.028 g, 0.023 mmol,
45%) as a glassy solid. 1H NMR (500 MHz, CDCl3) δ:
8.46 (bs, 1H), 5.74 (as, 1H, H-1), 5.39 (as, 1H, H-4), 5.28
(bs, 1H, H-2″’), 5.02 (ad, J = 10.8 Hz, 1H, H-3), 4.39–
4.46 (m, 1H, H-5), 4,39–4.27 (m, 1H, H-3″‘a), 4.17–4.11
(m, 4H, H-6a, H-6b, H-3″‘b, H-2′), 3.90 (bs, 4H, H-1″,
Fig. 1 Structure of the Tn-
mimetic 1, the native Tn antigen
2, the iron oxide
superparamagnetic nanoparticles
3, and glycopeptide 4
Fig. 2 Structure of the glycolipid 5 and the glycopeptide 6
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H-1″’), 3.57 (d, J = 11.7 Hz, 1H, H-2), 3.49–3.41 (m, 2H,
H-2″), 3.11–3.04 (m, 3H, H-3’a, CH2CO), 2.93 (bs, 1H,
H-3’b), 2.33–2.27 (m, 6H, CH2), 2.16 (s, 3H, COOCH3),
2.07 (s, 3H, COOCH3), 2.03 (s, 3H, COOCH3), 1.59 (bs,
4H, CH2), 1.27 (bs, 54H, CH2), 0.89 (t, J = 7 Hz, 6H,
CH3):
13C NMR (125 MHz, CDCl3) δ: 173.5 (Cq), 170.6
(Cq), 170.3 (Cq), 169.9 (Cq), 169.8 (Cq), 165.4 (Cq),
95.4 (C-1), 70.58 (C-2″’), 68.7 (C-5), 67.1 (C-4), 66.1
(C-3), 64.0 (C-2″,C-1″’), 62.61 (C-3″’,C-6), 61.45
(C-1″’), 51.82 (C-2′), 45.69 (CH2), 36.22 (C-2), 34.35,
34.0, 31.9, 29.7, 29.6, 29.6, 29.6, 29.4, 29.3, 29.3, 29.2,
29.2, 24.9, 24.8, 22.6, 20.6, 20.5, 18.4, 14.0, 8.5, 0.9: 1P
NMR (500 MHz, CDCl3) δ: 1.42 (s): ESI-MS: m/z Calcd
for C59H101N2O18PS: 1186.64 [M - H]
−; found: 1187.36.
Synthesis of 5
To a stirred solution of 9 (23.0 mg, 0.019 mmol) in a mixture
MeOH:CHCl3 (5:1, 1.2 mL) 0.953 mL of a K2CO3 solution
(0.02 M in MeOH) were added. The reaction mixture was
stirred for 1 h at rt. then a 0.01 M solution of acetic acid in
MeOHwas added to reach the pH = 7. The crude was purified
by gel filtration on Sephadex LH-20 column (2 × 20, d x h)
(MeOH) to give 5 (9.1 mg, 0.0085 mmol, 45%) as white
glassy solid. [α]25D = −21.4 (c 0.15 in CHCl3); 1H NMR
(500 MHz, CDCl3) δ: 5.69 (d, J1,2 = 2.7 Hz, 1H, H-1),
5.24–519 (m, 1H, H-2″’), 4.43–4.40 (A part of an ABX sys-
tem, JA,B = 12.1 Hz, JA,X = 3.15 Hz, 1H, H-3″‘a), 4.20–4.16
(m, 2H, H-2′, H-3″‘b), 4.08–3.96 (m, 4H, H-4, H-5, H-2″ or
H-1″’), 3.83–3.79 (A part of an ABX system, JA,B = 11.5 Hz,
JA,X = 6.0 Hz, 1H, H-6a), 3.79–3.76 (B part of an ABX sys-
tem, JB,A = 11.5 Hz, JB,X = 6.0 Hz, 1H, H-6b), 3.66–3.62 (m,
3H, H-3, H-2″ or H-1″’), 3.42–3.38 (m, 1H, H-1^a), 3.47 (dd,
J2,1 = 10.7 Hz, J2,3 = 2.8 Hz, 1H, H-2), 3.53–3-50 (m, 1H,
H-1^b), 2.86 (ad, J = 7.0 Hz, 2H, H-3’a, H-3’b), 2.33–26 (m,
2H, CH2CO), 1.60–1.59 (bs, 4H, CH2), 1.27 (bs, 54H, CH2),
0.89 (t, J = 7 Hz, 6H, CH3);
13C NMR (125 MHz, CDCl3) δ:
173.0 (Cq), 170.5 (Cq), 171.2 (Cq), 168.7 (Cq), 169.8 (Cq),
164.4 (Cq), 96.5 (C-1), 73.4 (C-4 o C-5), 70.4 (C-1″’ o C-2″),
68.8 (C-4 o C-5), 65.7 (C-3), 64.6 (C-2″ o C-1″’), 62.4
(C-3″’), 61.3 (C-6), 51.82 (C-2′), 40.8 (C-1″), 39.1 (C-2),
34.3 (CH2), 34.0, 31.7 (C-3′), 30.6, 29.6, 29.5, 29.4, 29.3,
29.2, 29.1, 29.0, 28.9, 24.9, 24.8, 22.5, 13.6, 0.6; ESI-MS:
m/z Calcd for C53H94N2O15PS: 1061.61 [M-H]
−; found
1061.33.
Synthesis of 6
Compounds 10 [44] (5.0 mg, 2.8 μmol), 7 (9.1 mg,
20.4 μmol) and PyBOP (17.3 mg, 33 μmol) were dis-
solved in 2 mL of DMF, and the pH was adjusted to 8–
9 by adding DIPEA (19 μL, 56 μmol). The solution
was stirred 2 h at room temperature, then the solvent
was evaporated under reduced pressure and diethyl ether
was added to precipitate the resulting acetylated glyco-
peptide that was used without further purification.
Analytical RP-HPLC: Rt = 14.3 min (C18, 214 nm, 5–
40% B in 20 min) ; ESI+ -MS: m/z ca l cd fo r
C158H206N22O70S6: 3726.2 [M + H]
+; found: 3725.7.
The crude mixture was dissolved in 5 mL of methanol
and NaOMe (pH 8) was added and the solution was
stirred at room temperature overnight. The reaction mix-
ture was next neutralized with Dowex 50 W–X8 (H+)
resin, filtered and purified by semi-preparative RP-
HPLC to afford 6 after lyophilisation. Yield: 51%
(4.3 mg); analytical RP-HPLC: Rt = 7.6 min (C18,
214 nm, 5–40% B in 20 min); ESI+-MS: m/z calcd for
C122H170N22O52S6Na: 2990.9 [M + Na]
+; found:
2990.2.
Synthesis of 11
The aldehyde-containing cyclopeptide 13 [45] (2.2 mg,
1.6 μmol) and α-ONH2-GalNAc [46–48] (4.4 mg,
0.19 mmol) were dissolved in 0.1% TFA in water (10 mM).
After 2 h stirring at 37 °C, the crude mixture was purified by
preparative HPLC without additional treatment. Yield: 76%
(3.2 mg); analytical RP-HPLC: Rt = 7.7 min (C18, 214 nm, 5–
4 0% B i n 2 0 m i n ) ; ES I + -MS : m / z c a l c d f o r
C110H175N28O52Na: 2744.20 [M + Na]
+; found: 2743.4.
Synthesis of 12
Compound 12 has been prepared from 13 and hydroxylamine
hydrochloride following the procedure described for 11.
Yield: 60% (2.4 mg); analytical RP-HPLC: Rt = 8.6 min
(C18, 214 nm, 5–40% B in 30 min); ESI
+-MS: m/z calcd for
C62H98N22O22: 1502.7 [M + H]
+; found: 1503.8.
Cell cultures
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from venous blood of healthy volunteers after
their informed consent by density gradient centrifugation
using Lymphocite Separation Medium (LSM 1077) (GE
Healtcare, Milan, Italy). After cell washing with
Phosphate Buffer Saline (PBS) containing 0.1% Fetal
Bovine Serum (FBS) (Carlo Erba, Milan, Italy) NK
cells were isolated by magnetic separation technique
using a negative selection isolation kit (Miltenyi
Biotec, Bologna, Italy). Cells were then labelled with
a cocktail of biotin-conjugated antibodies against
lineage-specific antigens (CD3, CD4, CD14, CD15,
CD19, CD36, CD123, CD235a) and labeled with a
cocktail of MicroBeads (Miltenyi Biotec). Non-NK cells
were separated using a Miltenyi Biotec MACS Column.
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NK cells were routinely purified to >90% by this
method.
K562 cells are a highly undifferentiated human
erythroleukemic cell line, which does not express
MHC class I molecules [49], and are a generous gift
by Prof. M.C. Mingari (Department of Experimental
Medicine, IRCCS AOU San Martino-IST, Genova,
Italy).
Human CD1d transfected THP-1 and mouse FF13 iNKT
hybridoma cells were kindly provided by Prof. Gennaro De
Libero (Department of Research, Experimental Immunology,
University Hospital Basel, Basel, CH). All cells were regular-
ly cultured in RPMI-1640 complete growth medium, contain-
ing 10% heat inactivated FBS, 100 μg/ml kanamycin
(SigmaAldrich, Milan, Italy), 1 mM sodium pyruvate
(Lonza, Basel, Switzerland), 2 mM L-glutamime, 1% MEM
amino acid solution (Lonza), 0.01 mM β-mercaptoethanol
(GE healtcare), and cultured in a humidified atmosphere
(5% CO2, 37 °C).
Calcein AM assay
PBMC cells were labeled with 1 μM Calcein-AM
(CAM) (Life Technologies, Monza, Italy) in serum-free
PBS for 15 min at 37 °C in the dark. After washing,
labelled cells were seeded in 24-well plates and then
treated with increasing concentrations (0.1–100 μM) of
each compound for 24–48 h at 37 °C in a humidified
incubator. After incubation, the cells of each well were
harvested, washed, labelled with propidium iodide (PI)
(SigmaAldrich), and cell viability was measured by flow
cytometry (FACSDiva Option, Becton Dickinson, Milan,
Italy). Live cells were identified as CAMhigh/PI¯, where-
as dead cells were CAMlow/PI+. The viability was cal-
culated by FACSDiva software and expressed as the
percentage of CAMhigh/PI¯ cell population relative to
compound-untreated cells (controls).
NK cell degranulation assay
NK cell degranulation was measured in vitro by deter-
mining the expression of CD107a, the lysosome-
associated membrane protein-1 (LAMP-1), as previously
described [49]. NK cells were untreated/treated with in-
creasing concentrations (0.1–10 μM) of each compound
for 24 h in presence of IL-2 (100 U/mL) (Peprotech,
Rocky Hill, New Jersey, United States), a cytokine com-
monly used for NK cell activation [50]. Thereafter, NK
cells were incubated with K562 cells at an effector/
tumor cell ratio of 1:1 for 1 h at 37 °C in presence
of anti-CD107a-Phycoerythrin (PE) (Miltenyi Biotec).
Monensin (BD GolgiStop™ reagent, BD Bioscences,
Milan, Italy) was added and cells incubated for 3 h at
37 °C. Cells were washed and CD107a expression mea-
sured as Mean Fluorescence Intensity (MFI) by using
FACSDiva software (BD Bioscience, Milan, Italy). To
detect spontaneous NK cell degranulation, a negative
control sample (NK cells without K562 target cells)
was always included, while to measure the basal re-
sponse of cells isolated NK cells were stimulated only
with IL-2 (100 U/mL) (controls). As positive control we
treated cells with 10 μM of 2,3-butanediol, which is a
NK cell-activator at this concentration [51, 52].
iNKT cell activation
THP-1 cells (5 × 104 /well) were incubated with in-
creasing concentrations (0.01–100 μM) of each com-
pound or (0.01–100 nM) of α-GalCer, in serum-free
medium for 2 h at 37 °C. iNKT hybridoma cells
(1 × 105/well) were then added, and the plates incubat-
ed in a 37 °C, 5% CO2, humidified incubator for 48 h.
Cell-free supernatants were collected and released IL-2
was measured by standard ELISA assay (R&D systems,
Minneapolis, MN) using rat anti-mouse IL-2 mAbs and
expressed in pg/ml (mean ± s.d.).
Statistical analysis
Results were expressed as means ± SEM of at least three
independent experiments run in triplicate. Statistical signifi-
cance was evaluated by the one-way ANOVA followed by
Student’s t-test for unpaired populations (Graph Pad
Software, Inc., San Diego, USA). Differences were consid-
ered statistically significant when p ≤ 0.05.
Results and discussion
Chemistry
The glycolipid 5 was prepared starting from the
peracetylated derivative 7 [37] (Scheme 1a). The tricy-
clic scaffold of 7 was efficiently obtained relying on an
unconventional and totally stereoselective inverse
electron-demand [4 + 2] Diels-Alder reaction between
suitably protected glycals and α,α’-dioxothiones as pre-
viously described by some of us [37].
The peracetylated derivative 7 (Scheme 1A) was
coupled with the commercially available 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine 8 using TBTU
[N ,N ,N _ ,N _ - t e t r am e t h y l -O - ( b e n z o t r i a z o l - 1
yl)uraniumtetrafluoroborate; 2.0 equiv.] and N-methyl
morpholine (NMM; 2.0 equiv.) as coupling agents. The
resulting fully protected glycolipid 9 was obtained in
60% yield as sodium salt, after treatment with a
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cation-exchange resin (Amberlist IR120, Na+ form). The
α-galactosyl 9 was deprotected with a diluted solution
of K2CO3 to give 5 in 45% yield, after purification by
column chromatography on Sephadex LH-20.
Glycopeptide 6 has been prepared from the cyclopeptide
scaffold 10 [44] displaying six free lysines and the protected
derivative 7 (Scheme 1B). The coupling reaction was per-
formed with PyBOP as coupling reagent in DMF to afford
the hexavalent acetylated compound that was subsequently
deprotected with sodium methanoate in methanol. The
resulting glycopeptide 6 was obtained in 51% yield after
RP-HPLC purification Compounds 11 and 12 have been syn-
thesized from cyclopeptide 13 [44] and α-ONH2-GalNAc
[45–48, 53] and hydroxylamine hydrochloride, respectively,
using the oxime ligation strategy described earlier [46–48,
53]. The conjugation reaction occurred in water with
0.1% of TFA and the conversion of 13 was found quan-
titative in both cases within 2 h at 37 °C. After RP-
HPLC purification, compounds 11 and 12 were obtained
in 76% and 60% yield, respectively.
b
a
Scheme 1 a Synthesis of the glycolipid 5; reagents and conditions: a)
TBTU, NMM, DMF/CHCl3/CH2Cl2, 15 h, rt., then Amberlite IR 120
Na+, 60%; b) K2CO3. MeOH/CH2Cl2, 1 h, rt., 45%. b Synthesis of the
glycoconjugates 11 and 12; reagents and conditions: a) i: 7, PyBOP,
DIPEA, DMF, rt., 2 h, then ii: MeONa/MeOH, rt., 18 h, 51%; b) i:
BocSer(tBu)OH, DIPEA, DMF, rt., 1 h; ii: 0.1% TFA in H2O, rt., 2 h;
iii: NaIO4, water, rt., 30 min, 88% (over 3 steps); c) 0.1% TFA in water,
rt., 1 h; α-ONH2-GalNAc for 11, 76%; HONH2.HCl for 12, 60%
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Biological assays
Cell viability
To evaluate the effect of compounds 1, 5, 6, 8, 11, 12 and α-
OMe-GalNAc on cell viability human PBMC, containing a
variable percentage of NK (from 2% to 18%), and iNKT cells
(from 0.1 to 2%) were used [54, 55]. PBMC were labelled
with CAM and incubated with increasing concentrations (0.1–
100 μM) of each compound for 24/48 h. Cells not exposed to
compounds were taken as negative controls. Cell viability,
evaluated by FACS, always resulted ≥90% at all concentra-
tions and times tested (see Fig. S1, S2), suggesting that all
compounds under study are non-toxic for PBMC and useful
for functional studies.
iNKT cell activation
To evaluate the ability of the glycolipid 5 to activate
iNKT cells a T cell-antigen presenting assay was used.
Mouse iNKT hybridoma cells (FF13; 5 × 104 cells/
well), selected for their ability to respond to alpha-
galactosylceramide (α-GalCer) presented by CD1d ex-
pressing cells [56], were co-cultured with CD1d-
transfected THP-1 cells (2.5 × 104 cells/well), previous-
ly (2 h) treated with increasing concentrations (0.01–
100 μM) of glycolipid 5. Furthermore, the activity of
this compound was compared with the 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine 8 and the α-OMe-
GalNAc (Fig. 3a), while the α-GalCer (0.01–100 nM)
was used as positive control for validation of the assay
(Fig. 3b).
IL-2 production, typically measured to assess the abilities
of α-GalCer to stimulate human or murine iNKT cell hybrid-
omas [57], was evaluated in the cell culture media after 48 h of
co-culture by ELISA.
Figure 3a shows that, as expected, only compounds
having a lipid moiety (both the 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine 8 and the glycolipid 5)
induced IL-2 release in a concentration-dependent
manner.
The maximum effec t s were : 457 ± 47 and
634 ± 23 pg/mL at 10 μM, and the EC50 measured
were 0.5 ± 0.02 and 0.7 ± 0.01, respectively. The abil-
ity of phospholipid 8 to induce iNKT cell activation has
been previously reported by Wu et al., [58] and present
data are consistent with this report. Conversely, both the
α-OMe-GalNAc and the Tn-mimetic 1 failed in induc-
ing iNKT cell activation at all concentrations tested.
Of note, when the Tn-mimetic antigen 1 was conju-
gated to the phospholipid 8 a significant increase (+ 40
± 5%; P ≤ 0.01) in the IL-2 release was measured,
compared to the phospholipid 8.
The overall data clearly demonstrate that the conju-
gation of Tn-mimetic 1 to a lipid architecture confers to
the antigen the ability to activate murine iNKT cells.
NK cell degranulation
To determine the effect of the glycopeptide 6 on NK
cell activity a short-term degranulation assay was per-
formed, by measuring the expression of CD107a [51,
52], a cell surface antigen whose expression well corre-
lates with the NK killing activity [49]. The activity of
the glycopeptide 6 was compared with that of the α-
OMe-GalNAc, the Tn-mimetic 1, the RAFT-based
glycopetide 11 containing six residue of GalNAc, and
the hexavalent RAFT-based peptide scaffold 12 (-
negative control). Cells treated with 10 μM of 2,3-
butanediol, a well-known NK cell-activator [50], were
always taken as positive controls (black bar).
As shown in the Fig. 4, both the α-OMe-GalNAc
and the Tn mimetic 1 resulted effectively in inducing
a higher CD107a expression compared to compound-
untreated cells (negative controls, vertical black line).
The maximum effects were: +65 ± 13% (P ≤ 0.01)
and +74 ± 26% (P ≤ 0.05) at 1 μM, respectively.
Fig. 3 a IL-2 release by iNKT
hybridoma cells upon stimulation
with 1, 5, 8 and α-OMe-GalNAc
(0.01–100 μM) and (b) α-GalCer
(0.01–100 nM)
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The conjugation of GalNAc or the Tn mimetic to
RAFT peptide (compounds 6 and 11) did not improve
cell responses in comparison to cells treated with mono-
valent un-conjugated antigens, probably because this
type of scaffold is not able to increase the selectivity
and the strength of receptor binding, a fundamental fea-
ture for eliciting efficient immune cell activations.
Conversely, the RAFT-based peptide 12 resulted effec-
tive at all the concentrations tested.
The overall results suggest that a peptide RAFT is an
unsuitable scaffold for the multivalent presentation of
these type of molecules, since itself could interact with
receptors, expressed on NK cells, specifically recogniz-
ing peptides.
From our data it is, however, reasonable to conclude that
both α-OMe-GalNAc and Tn mimetic 1 are able to activate
human NK cells, as 2,3-butanediol (positive control) does.
Conclusion
In summary, we reported here the synthesis of the glycolipid 5
and the hexavalent glycopeptide 6, containing one and six
copies of the rigid α-Tn mimetic 1, respectively. From our
data: i) all the tested compounds are biocompatible; ii) the
Tn mimetic 1 activates human NK cells and, when suitably
conjugated to a glycolipid, murine iNKT cells as well.
Since to induce a strong and efficient tumour
immunesurveillance a complex cross-talk between the innate
and adaptive immune system is strictly needed, the compound
1, able to activate both iNKT and NK cells, appears to be an
appealing lead, useful to act as a linker between the two im-
mune systems for promoting efficient immune responses.
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